Sezary syndrome is a leukemic form of cutaneous T-cell lymphoma which can also spread to other organs. Sezary cells are a type of white blood cells. In this condition, cancerous cells can be found in the blood, skin, and lymph nodes. Sezary syndrome also referred to as sezary erythroderma or Sezary’s lymphoma is an uncommon syndrome. It is more common in men with mean diagnosis age lying between 55 to 60 years. The exact cause for the sezary syndrome is yet to be established. Patient suffering from this have a compromised immunity. They have diffused skin rash which during the disease, tends to cover about 80% of the total body surface area. The other conditions linked with sezary syndrome are hypertrophied nails, alopecia, ectropion (outward turning of the lower eyelid), lichenification, and keratoderma.
With incapacitated immune system patients suffering from sezary syndrome come under vulnerable population who can have fatal blow from COVID-19. Furthermore, typical treatment methodologies include radiation therapy, photodynamic therapy and chemotherapy. These can further paralyze the immune system of the patients.
Sezary Syndrome Market: Drivers and Restraints
Historically there has been 2 to 3-fold increase in the number of cases of cutaneous T-cell lymphoma cases over the period of 25-30 years. With sezary syndrome constituting 3-5% of all cutaneous T-cell lymphoma cases, the market is bound to grow. Owing to various drugs in pipeline and emerging treatment therapies, the sezary syndrome treatment market is looking promising. Increased understanding in the fields of malignancy-related biomarkers has given momentum to the market as these facilitate early detection, improved prognostication and monitoring of disease burden which in turn would drive the global market for sezary syndrome treatment. Barriers to the sezary syndrome market are due to drugs and therapies in clinical trials which operate with the principle of hit and try basis. Uncertainty in potency of these is a major roadblock in the global market of sezary syndrome. Other restrainers for the global market of sezary syndrome may involve various policy and approval bottlenecks in the field of rare diseases.
Sezary Syndrome Market: Segmentation
The global sezary syndrome market is segmented based on the drug class, therapy type, distribution channel and region.
Based on the drug class, the global sezary syndrome treatment market is segments as:
Based on the therapy type, the global sezary syndrome treatment market is segments as:
Based on the distribution channel, the global sezary syndrome treatment market is segments as:
Sezary Syndrome: Overview
There have been reports of steady increase in the cases of cutaneous T-cell lymphoma over the past few years. With sezary syndrome accounting for 3-5% cases of cutaneous T-cell lymphoma, the market seems to be showing northward trend for the forecast period of 2020-2030. By distribution channel, hospital pharmacies are estimated to be growing at the fastest rate in the global sezary syndrome market owing to the supervision required by the medical specialists.
Recent developments include many immune-based therapies being researched for the treatment of sezary syndrome wherein immune balance restoration is the key. Additionally, major malignancy-related biomarkers are being explored for the diagnosis, prognosis and staging of sezary syndrome. Potency of therapeutic drugs like mogamulizumab, everolimus, duvelisib, brentuximab vedotin, denileukin diftitox, and lenalidomide etc. are being tested for better life experience of the patients.
Sezary Syndrome: Region-wise Outlook
Like most markets, North America is expected to be dominating the international sezary syndrome treatment market too owing to 3000 new cases of cutaneous T-cell lymphoma every year, out of which 15% account for sezary syndrome. However, increasing incidences of lymphoma worldwide would drive the global market for sezary syndrome in regions like Latin America, Asia-Pacific, Middle East and Africa.
Sezary Syndrome: Key Players
The key market players in the sezary syndrome market are Innate Pharma, Kyowa Kirin, Shionogi, Bioniz Therapeutics, Eisai, Bayer, Minophagen Pharmaceutical Co., Ltd, Novartis, STI Pharma, Gilead, Merck, Hikma, Seattle Genetics, Amerigen Pharmaceuticals.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report covers exhaust analysis on:
Regional analysis includes:
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.